ClinicalTrials.gg

Program

desethyloxybutynin

Also written as “NRX-101” and “NRX-101 Oral Capsule”.

Its studies are mostly in Bipolar Disorder · Depressive Disorder, Treatment-Resistant, led by NeuroRx.

Furthest: phase 3, since Nov 2, 20174 company-led studies, 2 open or runningNext primary completion: Dec 31, 2027 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
NeuroRx42 open or runningphase 3since Nov 2, 2017Nov 22, 2016Dec 31, 2027phase 3 · NCT07227103

Also a collaborator on its studies: target-health-inc.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Nov 22, 2016First study: phase 2 study in Bipolar DisorderFirst studyNCT02974010 · 22 enrolled · United States
  2. Nov 2, 2017Phase 3 study in Bipolar DisorderNCT03396068 · 72 enrolled · United States
  3. Jan 4, 2018Phase 3 study in Bipolar DisorderNCT03395392 · 74 enrolled · United States
  4. Nov 9, 2025Phase 3 study in Depressive Disorder, Treatment-ResistantNCT07227103 · 240 planned · United States

Ahead

  1. Dec 31, 2027Primary completion: phase 3 study in Depressive Disorder, Treatment-ResistantNCT07227103

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 4 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07227103Depressive Disorder, Treatment-Resistant · United States3RecruitingDec 31, 2027240
NCT03395392Bipolar Disorder · United States3CompletedFeb 28, 202474
NCT03396068Bipolar Disorder · United States3Active, not recruitingDec 31, 202472
NCT02974010Bipolar Disorder · United States2CompletedAug 31, 201822

How it is read

Names in the registry

  • “NRX-101”, 3 entries
  • “NRX-101 Oral Capsule”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.